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Abstract 
Human herpesvirus-6 (HHV-6) is a major cause of limbic encephalitis with a dismal 
prognosis after allogeneic hematopoietic stem cell transplantation (HSCT). A 
prospective, multicenter study was conducted to assess the safety and efficacy of 
preemptive therapy with foscarnet sodium (PFA) for the prevention of HHV-6 
encephalitis. Plasma HHV-6 DNA was measured thrice weekly from day 7 until day 
36 after umbilical cord blood transplantation (UCBT) or HSCT from 
HLA-haploidentical relatives. PFA, 90 mg/kg/day, was started when HHV-6 DNA 
exceeded 5  102 copies/ml. Mild and transient adverse events were associated with 
PFA in 7 of 8 patients. Twelve of 15 UCBT recipients became positive for HHV-6 
DNAemia, defined by greater than 1 x102 copies/ml of HHV-6 DNA in plasma. The 
virus exceeded 5  102 copies/ml in 7 patients, while none of the 5 HLA-haploidentical 
HSCT recipients became positive. One patient developed mild limbic encephalitis just 
after initial PFA administration. Preemptive PFA therapy is safe, but since HHV-6 
DNAemia can abruptly develop before neutrophil engraftment in UCBT recipients, 
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Introduction 
Umbilical cord blood (UCB) from unrelated donors has been successfully used as an 
alternative hematopoietic stem cell source for treatment of hematologic malignancies 
in patients who do not have HLA-matched bone marrow (BM) or peripheral blood 
stem cell (PBSC) donors. UCB transplantation (UCBT) has several advantages over 
BM transplantation (BMT) or PBSC transplantation (PBSCT) because of its rapid 
availability and lower risk of acute graft-versus-host disease (GVHD), even when there 
is a 1-3 HLA antigen mismatch (1-4). However, UCBT is associated with a higher risk 
of engraftment failure and more delayed immunological recovery than BMT and 
PBSCT (5-10). 
Recently, human herpesvirus-6 (HHV-6) has been recognized as an important 
pathogen in allogeneic hematopoietic stem cell transplantation (HSCT) (11-14). The 
reactivation of HHV-6 occurs around the time of neutrophil engraftment and 
occasionally causes limbic encephalitis, which is characterized by a loss of short-term 
memory and abnormal hippocampal findings on magnetic resonance (MR) images (15). 
Although limbic encephalitis due to HHV-6 used to be a rare complication after 
conventional HSCT, it is becoming one of the most serious complications after HSCT 
as the number of UCBT increases (16, 17). 
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HHV-6, a causal virus of infantile exanthem subitum, latently infects almost all 
Japanese adults. HHV-6 DNA is detected in the plasma of 33% to 48% patients treated 
with HSCT but is undetectable in plasma from healthy individuals or from UCB (18, 
19). HHV-6 DNA becomes detectable around day 9 or later after HSCT, and high 
HHV-6 DNA copy numbers are associated with development of BM suppression 
(20-22). Foscarnet sodium (PFA) is thought to be preferable to ganciclovir (GCV) as 
an anti-cytomegalovirus (CMV) drug used in the early post-transplant period because 
it has less BM toxicity than GCV (23), however, the safety of PFA administration 
early after HSCT has not been established in UCBT recipients. Ogata et al. (24) 
reported that the HHV-6 DNA copy number in the peripheral blood increased 100-fold 
within 3 to 4 days in some cases, and limbic encephalitis developed in UCBT 
recipients when the HHV-6 DNA copy number in plasma exceeded 1  104/ml. 
According to their report, once a week monitoring of HHV-6 DNA in plasma followed 
by preemptive administration of PFA was insufficient to prevent limbic encephalitis. 
More frequent monitoring of HHV-6 DNA such as three times a week, early after 
HSCT and preemptive administration of PFA based on positive results, defined as a 
low viral copy number (5  102 copy/ml), may help prevent HHV-6 encephalitis. To 
examine this hypothesis, we conducted a prospective, multicenter study of preemptive 
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therapy of HHV-6 infection with low-dose PFA for high-risk patients after HSCT. 
This study documented the safety and efficacy of the preemptive administration of 
PFA in the prevention of severe HHV-6 encephalitis. 
 
Methods 
Endpoint of this study 
This study was conducted primarily to assess the incidence of adverse events (AEs) 
associated with PFA administration until day 36 after HSCT because the safety of 
using PFA early after HSCT has not been established. The secondary endpoint was to 
assess the efficacy of preemptive administration of PFA in preventing the development 
of limbic encephalitis, as well as in reducing the amount of plasma HHV-6 DNA. 
 
Study design 
Eligible patients were aged from 16 to 75 years with hematologic disorders refractory to 
conventional therapy and were considered to require UCBT or HLA 1-haplotype 
matched HSCT (haploidentical HSCT) from relatives due to the unavailability of an 
HLA-identical relative or a suitable unrelated donor. Informed consent was obtained 
 
 
8 / 27 
 
from all subjects according to the Declaration of Helsinki, and this study protocol was 
approved by the institutional ethics committee (No. 5434). This trial was registered to 
UMIN Clinical Trials Registry (UMIN-CTR; http://www.umin.ac.jp/ctr/index.htm) 
under identifier UMIN000001346. HLA matching was evaluated with molecular typing. 
Patients with high serum creatinine levels and/or lower estimated glomerular filtration 
rate greater than grade 2, and/or other organ dysfunctions greater than grade 3 defined 
by the Common Terminology Criteria ver.3.0 for Adverse Events (CTCAE) of the 
National Cancer Institute, USA, were excluded. Regimens for preconditioning and 
GVHD prophylaxis were not specified. The serum HHV-6 IgG titer before 
transplantation was determined by immunofluorescence assay. Peripheral blood samples 
were obtained on every Monday, Wednesday, and Friday from day 7 to day 36 after 
HSCT, and frozen plasma samples were sent to SRL, Inc (Tokyo, Japan) to measure the 
amount of HHV-6 DNA using a real-time polymerase chain reaction (PCR) method on 
the following day (25, 26). Administration of PFA, 90 mg/kg/day, was started on the day 
when the amount of plasma HHV-6 DNA exceeded 5  102 copies/ml. The PFA dose 
was increased to 180 mg/kg/day when the plasma HHV-6 DNA copy number increased 
to more than 1  105/ml or when symptoms suggestive of encephalitis appeared. PFA 
was discontinued when the plasma HHV-6 DNA was negative on 3 consecutive 
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occasions. If the patients’ creatinine clearance fell below 1.4 ml/min/kg, the PFA dose 
was reduced according to the manufacturer’s instructions. 
 
Statistical analysis 
The following variables related to patients and their clinical data were compared among 
the groups using Fisher’s exact probability test or the Mann-Whitney U test: gender 
(male vs. female), HHV-6 IgG titer before HSCT, intensity of the conditioning regimen 
(myeloablative vs. reduced-intensity conditioning), prophylactic regimens for GVHD 
(cyclosporine-based vs. tacrolimus-based), transplanted cell number, type of HSCT 
(UCBT vs. haploidentical HSCT), date of WBCs > 0.1  109/l, date of neutrophils > 0.5 
 109/l, date of developing HHV-6 DNAemia (defined as the state characterized by the 
presence of HHV-6 DNA greater than 1  102 copies/ml in plasma), duration of HHV-6 
DNAemia, and development of CMV antigenemia (positive vs. negative). All P values 
were two-sided with values less than 0.05 being considered statistically significant. 
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Patients’ characteristics 
A total of 21 patients was enrolled from 4 different institutions between September 
2007 and February 2009. The characteristics of the patients are summarized in Table 1; 
their median age was 51 years (range, 18 - 72 years). Eight patients received 
myeloablative preparative regimens, and 13 patients received reduced-intensity 
conditioning before HSCT. Sixteen patients received a UCB graft, while 5 patients 
were grafted with PBSCs from HLA-haploidentical donors. GVHD prophylaxis 
regimens were cyclosporine in 5 patients and tacrolimus in 16 patients. All patients 
were seropositive for CMV without CMV disease before HSCT. One patient (UPN 2) 
who received PBSCT developed primary graft rejection due to anti-HLA class I 
antibodies specific to a donor’s mismatched allele and received second transplantation 
with UCB. This patient was re-registered as UPN 4. One UCBT patient (UPN 16) was 
excluded from the analysis because of early death (on day 4) after HSCT due to 
hepatic failure associated with primary biliary cirrhosis. 
 
Toxicities of preemptive PFA administration 
In 15 patients who received UCB grafts, AEs graded greater than 3 by CTCAE, were 
observed in 7 of the 8 patients (88%) treated by PFA and 4 of the 7 patients (57%) not 
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treated with PFA (Table 2a). Most of these AEs associated with PFA treatment were 
electrolyte abnormalities such as hypernatremia, hypokalemia, and hypomagnesemia 
(Table 2b). These abnormalities improved promptly after appropriate fluid therapy. 
Severe renal dysfunction did not develop in any of the PFA-treated patients, though 
grade 2 renal dysfunction, such as a low glomerular filtration rate, was observed in 2 
PFA-treated patients. Other grade 3 AEs included a transient rise in the aspartate 
aminotransferase level requiring no treatment and a systemic skin rash that disappeared 
after the administration of 100 mg hydrocortisone succinate. Four patients were dropped 
out of this study and died; 2 patients developed HHV-6 DNAemia not requiring PFA 
treatment, and the other 2 patients remained negative for HHV-6 DNA during the 
observation period. The causes of death were hepatic veno-occlusive disease, 
bacteremia leading to pulmonary alveolar hemorrhage, thrombotic microangiopathy, 
and bacteremia. Both attending physicians and central reviewers judged that there was 
no relationship between PFA administration and the causes of death in all 4 cases. 
 
Development of HHV-6 DNAemia 
Of 15 UCBT recipients, 12 (80%) developed HHV-6 DNAemia. The HHV-6 DNA 
copy number exceeded 5  102/ml in 7 of the 11 patients; 1 patient (UPN 19) was 
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erroneously treated with PFA when the HHV-6 copy number was less than 5  102/ml 
and was therefore excluded from this analysis. On the other hand, all 5 haploidentical 
HSCT recipients remained negative for HHV-6 DNA in their plasma during the 
observation period (P < 0.004). Therefore, further analyses focused on UCBT 
recipients. When the clinical characteristics were compared between patients positive 
for HHV-6 DNAemia (n = 12) and those who did not develop HHV-6 DNAemia (n = 
3), on univariate analysis there were no significant differences in age, sex, HHV-6 IgG 
titer (tested in 11 cases), intensity of conditioning regimens, transplanted cell number, 
GVHD prophylactic regimens, date of WBCs > 0.1  109/l, and date of neutrophils > 
0.5  109/l (Table 3). Table 4 shows the comparison of the characteristics of HHV-6 
DNAemia between patients who eventually required PFA due to an increase in HHV-6 
DNA copy number to greater than 5  102 /ml and those who did not require PFA 
treatment after HSCT. In 6 of 7 treated patients, the HHV-6 DNA copy number was 
greater than 5  102 copies/ml at the time when HHV-6 DNA was detected for the first 
time (median, 2.4  103 copies/ml). On the other hand, the HHV-6 DNA copy number 
was significantly lower in untreated patients at the time of the first HHV-6 DNA 
detection than in treated patients (median, 1.1  102 copies/ml, P = 0.01). HHV-6 
DNAemia developed significantly later in patients who did not eventually require PFA 
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treatment than in patients who required PFA treatment (median, day 22 vs. day 17, P < 
0.02). The duration of HHV-6 DNAemia was significantly shorter in untreated patients 
than in the PFA-treated patients (median, 2 days vs. 9 days, P < 0.008). 
 
Relationship between the time for neutrophil engraftment and that for the development 
of HHV-6 DNAemia 
Figure 1 illustrates the changes in the HHV-6 copy number in 7 patients who required 
PFA administration. These patients achieved neutrophils > 0.5  109/l and WBCs > 0.1 
 109/l on day 13-33 (median, day 22) and day 10-20 (median, day 14), respectively. 
HHV-6 DNAemia developed prior to the day of neutrophils > 0.5  109/l in 5 of 7 
patients and WBCs > 0.1  109/l in 3 of 7 patients, indicating that HHV-6 DNAemia 
occurs much earlier than neutrophil engraftment in UCBT recipients. 
 
Effect of preemptive PFA administration 
PFA, 90 mg/kg/day, was administered to 7 patients whose HHV-6 DNA copy number 
exceeded 5  102 copies/ml from day 15 to day 20 (median, day 17) after UCBT. The 
amount of HHV-6 DNA in the plasma decreased on the next day of PFA 
administration in 4 of the 7 patients, while 3 other patients required 3-4 days until the 
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copy number decreased (Figure 1, red arrows). In 2 patients, the HHV-6 DNA copy 
numbers exceeded 1  104/ml (UPN 1 and UPN 21), a level that predicts the 
development of limbic encephalitis, on the next day of first PFA administration with 
no symptoms suggestive of encephalitis, and the HHV-6 DNA copy number decreased 
3-4 days after PFA administration. Of 15 patients who achieved neutrophil 
engraftment after HSCT, 4 of 7 patients who did not receive PFA developed CMV 
antigenemia within 60 days after HSCT, while no patients treated with PFA developed 
CMV antigenemia (P < 0.03). 
Limbic encephalitis developed in 1 patient (UPN 9) who received preemptive 
PFA administration. This patient showed an increase in the HHV-6 DNA copy number 
on day 17 after UCBT (Figure 2). When the first PFA administration was started at 8 
pm on day 18 by 3 hours’ intravenous drip infusion, there were no neurological 
symptoms. The patient was found to be unconscious at his bedside around 11 PM 
during the PFA infusion. A magnetic resonance study revealed asymmetric 
enhancement of the limbic cortex on fluid-attenuated inversion-recovery (FLAIR) 
imaging. Cerebrospinal fluid was not examined because of the patient’s low platelet 
count. Electroencephalography showed periodic, lateralized, epileptiform discharges 
and sharp-and-slow-wave complexes, a finding compatible with HHV-6 encephalitis. 
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Five days after increasing the PFA dose from 90 mg/kg/day to 180 mg/kg/day, the 
patient’s consciousness level improved. The patient achieved WBCs > 0.1  109/l and 
neutrophils > 0.5  109/l on day 19 and day 26, respectively. Currently, he is an 
outpatient with mild motor neuropathy but no impaired memory. 
 
Discussion 
PFA has been used for the treatment of HHV-6 encephalitis (27-29), however, the 
safety of initiating the administration of PFA before neutrophil engraftment has not 
been established. Although PFA administration is not usually associated with BM 
suppression, it may impair UCB engraftment when it is used soon after transplantation. 
Moreover, PFA frequently causes renal dysfunction. Two papers described the 
effectiveness and safety of low-dose PFA treatment for CMV infection after HSCT (23, 
30), but little is known about the toxicity and the efficacy of its administration in the 
early period after HSCT so far because most patients received PFA treatment on day 
30 or later. Previous studies documented that HHV-6 DNAemia developed as early as 
day 15 after UCBT (17). One of our patients (UPN 21) developed HHV-6 DNAemia, 
with a copy number of 7.3  103/ml on day 10 after UCBT. Therefore, it is necessary 
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to confirm the safety of the use of anti-HHV-6 agents before neutrophil engraftment. 
The current study revealed that low-dose PFA could be administered to UCBT 
recipients with acceptable toxicities even in the very early period after HSCT. Greater 
than grade 3 AEs occurred in 7 of 8 PFA-treated patients and 4 of 7 PFA-untreated 
patients, and there appears to be a tendency toward a higher incidence of severe AEs in 
PFA-treated patients than in untreated patients. However, the total number of greater 
than grade 3 AEs that occurred in the 8 PFA-treated patients was 8, similar to the 6 in 
the 7 untreated patients. A skin rash developed on day 17 and day 20, just before 
starting PFA treatment in 2 patients. Because it disappeared quickly with PFA 
treatment, the rash may have been associated with HHV-6 reactivation (31, 32). 
Several risk factors have been identified for HHV-6 reactivation after HSCT. These 
include younger age, treatment with steroid, low-titers of anti-HHV-6 IgG before 
HSCT, and development of GVHD (14, 24, 33, 34). The use of transplantation from 
alternative graft sources, such as HLA-mismatched BM and UCB, is another risk 
factor for HHV-6 reactivation (24, 34-36). In the present study, UCBT was more 
associated with HHV-6 reactivation than haploidentical PBSCT. Of note, none of the 
patients who enrolled in this study developed acute GVHD and required corticosteroid 
treatment as a result, except for short-acting corticosteroids given to ameliorate fever 
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or allergic symptoms. It is conceivable that PFA administration with this dosage may 
mitigate the secretion of inflammatory cytokines such as IFN- or TNF- from 
immune cells by inhibiting HHV-6 reactivation. This possibility needs to be examined 
in a prospective study involving a larger number of patients. 
Two groups have documented the favorable results of prophylactic GCV 
administration for HHV-6 infection after neutrophil engraftment (37, 38). In the 
present study, 5 of the 7 patients whose DNA copy number later exceeded 5  102/ml 
became positive for HHV-6 DNA prior to reaching neutrophils > 0.5 x109/l, indicating 
the necessity of other strategies for preventing HHV-6 infection, because GCV is 
associated with BM suppression. The present study showed that the earlier the 
reactivation occurred, the more the HHV-6 viral load increased; the viral load 
increased within 48 hours after the negative test to a level greater than 5  102/ml. 
Thus, it may be important to ensure that the test result for HHV-6 DNA measurement 
can be returned on the day of blood sampling, or at least by the following morning, in 
order to make the preemptive approach successful. However, most hospitals are unable 
to get results in this short of time. It is possible that prophylactic PFA administration 
before the time of leukocyte recovery would be a more reasonable approach rather 
than preemptive PFA administration following the identification of HHV-6 DNA. 
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To prevent limbic encephalitis, what needs to be treated with PFA is HHV-6 
DNAemia that occurs before the rise in the leukocyte count. Therefore, prophylactic 
administration of PFA from day 7 or earlier to day 20 may be a more reasonable 
approach than preemptive PFA administration guided by HHV-6 DNA detection to 
prevent limbic encephalitis in UCBT recipients. The efficacy of such prophylactic 
administration of PFA after UCBT is now being examined in a prospective study. 
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Figure legends 
Figure 1. Relationship between the time for neutrophil engraftment and the time for 
the development of DNAemia in patients treated with PFA. Changes in the HHV-6 
DNA copy number in each patient are shown. The horizontal axis shows days after the 
time for neutrophil engraftment (> 0.5  109/l, (A)) and the time for leukocytes > 0.1  
109/l (B). The arrows indicate when PFA was started. 
Figure 2. Clinical course of a patient who developed HHV-6 limbic encephalopathy. 
(A) MR imaging of the patient. A high intensity area is observed at the cingulate gyrus, 
left insula, left hippocampus, and the gyrus parahippocampalis. (B) The patient’s 
clinical course. 
n=21






1CR → rej 1
1rel 1
2CR or worse 3
ALL, 2CR 2










PBSC * Exclude 1 case from further analysis because ofearly death after transplantation.
UCB
Regimen
Myeloablative, TBI base 8
RIC 13*







Abbraviations: ATG; antithymocyte globulin, ALL;
acute lymphoblastic leukemia, AML; acute myeloid
leukemia, Campath; alemtuzumab, CB; cord blood,
CML; chronic myelogenous leukemia, CP; chronic
phase, CR; complete remission, CY;
cyclophosphamide, CyA; cyclosporine A, FK506;
tacrolimus, Flu; fludarabine, GVHD; graft-versus-
host disease, L-PAM; melphalan, MDS;
myelodysplastic syndrome, NHL; non-Hodgkin's
lymphoma, PBSC; peripheral blood stem cell, PLL;
prolymphocytic leukemia, rej; rejection, RAEB;
refractory anemia with excess blasts, rel; relapse,
RIC; reduced intensity conditiong, TBI; total body
irradiation, VP16; etoposide.
Table 1. Patients characteristics
5
1.7-14.6 x106/kg (Median: 3.5)
16*





Patients with PFA treatment (n = 8) 8 7
Patients without PFA treatment (n = 7) 4 4
Table 2. Adverse events in patients who received UCB grafts
a. Number of cases who develop adverse events greater than grade 2 / 3
Patients with PFA
treatment (n = 8)
Patients without PFA













Table 2. Adverse events in patients who received UCB grafts
b. Number of events who develop adverse events greater than grade 2 / 3
These adverse events were graded by the Common Terminology
Criteria ver. 3.0 for Adverse Events (CTCAE) of the National
Cancer Institute, USA. One patient who erroneously treated with
PFA at under predetermined threshold was included in this analysis.
Abbraviation: PFA; foscarnet sodium, UCB; unrelated cord blood.
Positive for
HHV-6 (n = 12)
Negative for
HHV-6 (n = 3)
Age, range (median) 32 - 72 (52) 14 - 64 (21)
Gender (M : F) 6 : 6 2 : 1
HHV-6 IgG titer, range (median) 20 - 1280 (80) 20 - 320 (20)
Regimen (Myeloablative vs. RIC) 5 : 7 1 : 2
GVHD prophylaxis (CyA vs. FK506) 5 : 7 0 : 3
Number of transplanted cells, range (median) 1.6 - 3.5 (2.7) 1.4 - 2.3 (2.1)
Date of  WBCs > 0.1 x 109/l, range (median) 10 - 23 (16) 10 - 20 (15)
Date of neutrophils > 0.5 x 109/l, range (median 13 - 33 (27) 25
Table 3. Comparison of clinical features between HHV-6 DNAemia positive and negative
patients in UCBT recipients
Abbraviations: CyA; cyclosporine A, FK506; tacrolimus, GVHD; graft-versus-host disease, HHV-6;
human herpes virus-6, RIC; reduced intensity conditiong, UCBT; umbilical cord blood transplantation.
Table 4. Characteristics of HHV-6 DNAemia-positive UCBT recipients and their HHV-6 DNAemia
Patients who required PFA (n=7)
















number at peak  (/ml)
1 50 M 13 15 15 1.0 x104 2.3 x104
4 40 F 20 27 17 4.6 x102 5.0 x102
5 60 F 17 22 20 1.6 x103 3.0 x103
7 54 M 14 21 19 2.4 x103 2.4 x103
8 72 F 10 13 15 2.8 x103 2.8 x103
9 49 M 19 26 17 1.2 x103 1.2 x103
21 57 M 10 33 10 7.3 x103 1.7 x104
Patients who did not require PFA (n=4)
11 32 M 17 24 31 1.0 x102 1.0 x102
12 68 F 12 17 21 1.0 x102 3.1 x102
17 56 F 22 NA 22 1.1 x102 1.1 x102
18 37 M 23 NA 21 1.6 x102 1.6 x102
One patient who was erroneously treated with PFA at under the predetermined threshold was excluded in t
Abbreviations: HHV-6, human herpes virus-6; NA, not achieved; PFA, foscarnet sodium; UCBT, umbilica
transplantation.
Duration of
HHV-6
DNAemia
(day)
9
7
9
7
9
4
9
2
7
1
2
this analysis.
al cord blood


